Pipeline

With currently some 70 distinct drugs in research and development, MorphoSys has one of the broadest antibody pipelines in the biotechnology industry. 19 compounds are already being evaluated in clinical trials and tested as options for treatment of severe and in many cases life-threatening diseases. The Company’s product pipeline comprises both partnered and proprietary antibody therapeutic development programs, as shown below:

Pipeline

Discovery Preclinic Phase 1 Phase 2 Phase 3 Market
MOR103

MOR103 developed by MorphoSys

  • A fully human HuCAL antibody for the treatment of inflammatory diseases like rheumatoid arthritis or multiple sclerosis
  • Target: Granulocyte macrophage colony-stimulating factor (GM-CSF)

Additional information:

 

MOR103 developed by MorphoSys

  • A fully human HuCAL antibody for the treatment of inflammatory diseases like rheumatoid arthritis or multiple sclerosis
  • Target: Granulocyte macrophage colony-stimulating factor (GM-CSF)

Additional information:

Novartis
BYM338, Novartis

BYM338 developed by Novartis

  • A fully human HuCAL-based antibody to treat musculoskeletal diseases

Additional information:

BHQ880, Novartis

BHQ880 developed by Novartis

  • A fully human HuCAL-based antibody to treat osteolytic bone disease in multiple myeloma patients
  • Target: Dickkopf-1 (DKK-1)

Additional Information:

CNTO 888, Janssen

CNTO 888 developed by Janssen Biotech

  • A fully human HuCAL-based antibody to treat Idiopathic Pulmonary Fibrosis & solid tumors.
  • Target: Monocyte chemoattractant protein-1 (MCP-1)

Additional Information:

 

CNTO 888 developed by Janssen Biotech

  • A fully human HuCAL-based antibody to treat Idiopathic Pulmonary Fibrosis & solid tumors.
  • Target: Monocyte chemoattractant protein-1 (MCP-1)

Additional Information:

CNTO 1959, Janssen

CNTO 1959 developed by Janssen Biotech

  • A fully human HuCAL-based antibody to treat Psoriasis

Additional Information:

Gantenerumab, Roche

Gantenerumab developed by Roche

  • A fully human HuCAL-based antibody to treat Alzheimer‘s disease
  • Target: Amyloid-beta

Additional Information:

MOR208

MOR208 developed by MorphoSys

  • A Fc-optimized antibody to treat Chronic Lymphocytic Leukemia
  • Target: CD19

Additional Information:

MOR202

MOR202 developed by MorphoSys

  • A fully human HuCAL-based antibody to treat Multiple Myeloma
  • Target: CD38

Additional Information:

CNTO 3157, Janssen

CNTO 3157 developed by Janssen Biotech

  • A fully human HuCAL-based antibody to treat Asthma

Additional Information:

 

Janssen Biotech
BAY 94-9343, Bayer HealthCare

BAY 94-9343 developed by Bayer HealthCare

  • A fully human HuCAL-based antibody drug conjugate to treat mesotheliomas and ovarian and pancreatic carcinomas
  • Target: Mesothelin

Additional Information:

Novartis
Novartis
Boehringer Ingelheim
Pfizer
OMP-59R5, OncoMed

OMP-59R5 developed by OncoMed

 

  • A fully human HuCAL-based antibody to treat solid tumors
  • Target: Notch receptor

Additional Information:

OMP-18R5, OncoMed

OMP-18R5, OncoMed

  • A fully human HuCAL-based antibody to treat solid tumors
  • Target: Wnt signaling pathway 

Additional information:

25 Partnered Programs
4 Proprietary Programs
Co-development MorphoSys / Novartis (2)
27 Partnered Programs
 

Partnered Programs

Proprietary Programs

Pipeline Generator

 

Clinical Trials

MorphoSys is currently involved in several active clinical trials.